United States
Germany
Japan
United Kingdom
China
ELMO1 (NM_001039459) Human Tagged ORF Clone Lentiviral Particle
CAT＃: RC215722L1V
- LentiORF®
-
Lenti ORF particles, ELMO1 (Myc-DDK tagged) - Human engulfment and cell motility 1 (ELMO1), transcript variant 3, 200ul, >10^7 TU/mL
Need custom lentivirus service?
Get a free quote
CNY 7,410.00
货期*
详询
规格
Product images
经常一起买 (3)
Specifications
| Product Data | |
| Product Name | ELMO1 (NM_001039459) Human Tagged ORF Clone Lentiviral Particle |
| Synonyms | CED-12; CED12; ELMO-1 |
| Vector | pLenti-C-Myc-DDK |
| ACCN | NM_001039459 |
| ORF Size | 2181 bp |
| Sequence Data |
The ORF insert of this clone is exactly the same as(RC215722).
|
| OTI Disclaimer | The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info |
| OTI Annotation | This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. |
| Reference Data | |
| RefSeq | NM_001039459.1 |
| RefSeq Size | 3590 bp |
| RefSeq ORF | 744 bp |
| Locus ID | 9844 |
| Protein Pathways | Chemokine signaling pathway |
| MW | 83.8 kDa |
| Gene Summary | This gene encodes a member of the engulfment and cell motility protein family. These proteins interact with dedicator of cytokinesis proteins to promote phagocytosis and cell migration. Increased expression of this gene and dedicator of cytokinesis 1 may promote glioma cell invasion, and single nucleotide polymorphisms in this gene may be associated with diabetic nephropathy. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2013] |
Documents
| Product Manuals |
| FAQs |
| SDS |
Resources
You may also need
Customer
Reviews
Loading...
